EE/LNG for Healthy Female Participants

"The safety of EE/LNG is tentatively rated at 1, as this initial clinical trial has only provided minimal data to prove its efficacy and security."

"This clinical trial is seeking 24 female patients between the ages of 35 and 75 years old to participate. To qualify, volunteers must provide written consent before any study-specific activities, be capable of adhering to all protocol requirements, possess healthy veins for cannulation or repeated venipuncture, have gone through postmenopausal transition (as evidenced by amenorrhea lasting 12 months since ceasing exogenous hormones with FSH levels above 40 mIU/mL), underwent irreversible surgical sterilization such as hysterectomy or bilateral oophorectomy/salpingectomy but not tubal ligation and finally present a BMI ranging from"

"Affirmative, the research is still recruiting subjects as indicated on clinicaltrials.gov. It was initially posted on August 24th 2022 and updated most recently on November 4th 2022; it seeks to include up to 24 patients from a single site in its trial."

"Affirmative. Clinicaltrials.gov confirms that this medical trial, which was initially uploaded on August 24th 2022 is in search of participants as its last update was November 4th 2022. The research team has to enlist a total of 24 individuals from 1 site."

"The primary endpoint of this research is AUClast, which will be evaluated over the span of Day 1 and 15. Secondary objectives encompass Cmax, tmax, and a count of participants with adverse events. The pharmacokinetics (PK) properties in healthy female volunteers not capable of having children are also being assessed to determine safety and tolerability when combined with EE & LNG drugs."

"For this clinical trial, only individuals between the ages of 35 and 75 are eligible to enroll."